The Future of Blood Testing Is the Immunome

It is increasingly clear that an extraordinarily diverse range of clinically important conditions-including infections, vaccinations, autoimmune diseases, transplants, transfusion reactions, aging, and cancers-leave telltale signatures in the millions of V(D)J-rearranged antibody and T cell receptor [TR per the Human Genome Organization (HUGO) nomenclature but more commonly known as TCR] genes collectively expressed by a person's B cells (antibodies) and T cells. We refer to these as the immunome. Because of its diversity and complexity, the immunome provides singular opportunities for advancing personalized medicine by serving as the substrate for a highly multiplexed, near-universal blood test. Here we discuss some of these opportunities, the current state of immunome-based diagnostics, and highlight some of the challenges involved. We conclude with a call to clinicians, researchers, and others to join efforts with the Adaptive Immune Receptor Repertoire Community (AIRR-C) to realize the diagnostic potential of the immunome.

Automated summary

The complex and diverse immunome, which consists of V(D)J-rearranged antibody and T cell receptor genes expressed by B cells and T cells, presents unique opportunities for advancing personalized medicine through a highly multiplexed blood test. The current state of immunome-based diagnostics involves both opportunities and challenges, and there is a call for clinicians, researchers, and others to join efforts to realize the diagnostic potential of the immunome.